James O Lindsay
Overview
Explore the profile of James O Lindsay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
4817
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noor N, Radford S, Choodari-Oskooei B, Gordon M, Hart A, Hepburn T, et al.
Nat Rev Gastroenterol Hepatol
. 2025 Mar;
PMID: 40045038
No abstract available.
2.
Panaccione R, Ferrante M, Dotan I, Panes J, Hisamatsu T, Bossuyt P, et al.
Clin Gastroenterol Hepatol
. 2025 Feb;
PMID: 39909280
Background & Aims: The efficacy and safety of extended treatment with risankizumab (RZB), an anti-interleukin-23 p19 monoclonal antibody, were evaluated in patients with moderate to severe Crohn's disease (CD) who...
3.
Wyatt N, Watson H, Young G, Doona M, Tilling N, Allerton D, et al.
EBioMedicine
. 2025 Jan;
112:105550.
PMID: 39742562
Background: Large-scale multicentre studies are needed to understand complex relationships between the gut microbiota, health and disease. Interrogating the mucosal microbiota may identify important biology not captured by stool analysis....
4.
Roukas C, Miller L, Cleirigh Buttner F, Hamborg T, Stagg I, Hart A, et al.
United European Gastroenterol J
. 2024 Oct;
PMID: 39425758
Background And Aims: People with inflammatory bowel disease (IBD) often experience pain, fatigue and bowel incontinence and are at an increased risk of anxiety and depression. Our aim was to...
5.
Peyrin-Biroulet L, Chapman J, Colombel J, Caprioli F, DHaens G, Ferrante M, et al.
N Engl J Med
. 2024 Jul;
391(3):213-223.
PMID: 39018531
Background: The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown. Methods: In this phase 3b, multicenter, open-label, randomized, controlled trial with blinded...
6.
Siegel C, Rai V, Outtier A, Vermeire S, Law C, Sands B, et al.
J Crohns Colitis
. 2024 Jun;
PMID: 38908002
Background: Clinical trial recruitment for patients with inflammatory bowel disease (IBD) has become more challenging over time. We aimed to develop recommendations for broadening IBD clinical trial eligibility to improve...
7.
Tyler C, Hoti I, Griffiths D, Cuff S, Andrews R, Keisker M, et al.
Discov Immunol
. 2024 Jun;
3(1):kyae008.
PMID: 38903247
Direct interaction between T-cells exerts a major influence on tissue immunity and inflammation across multiple body sites including the human gut, which is highly enriched in 'unconventional' lymphocytes such as...
8.
Rodger B, Stagg A, Lindsay J
Front Immunol
. 2024 May;
15:1415914.
PMID: 38817613
Tissue-resident memory T cells (T) are long-lived memory lymphocytes that persist in non-lymphoid tissues and provide the first line of defence against invading pathogens. They adapt to their environment in...
9.
Wyatt N, Watson H, Anderson C, Kennedy N, Raine T, Ahmad T, et al.
BMJ Open
. 2024 Apr;
14(4):e073639.
PMID: 38631839
Introduction: Characterised by chronic inflammation of the gastrointestinal tract, inflammatory bowel disease (IBD) symptoms including diarrhoea, abdominal pain and fatigue can significantly impact patient's quality of life. Therapeutic developments in...
10.
Peyrin-Biroulet L, Panaccione R, Louis E, Atreya R, Rubin D, Lindsay J, et al.
Clin Gastroenterol Hepatol
. 2024 Mar;
22(10):2096-2106.
PMID: 38492904
Background & Aims: Upadacitinib, an oral Janus kinase inhibitor, achieved significantly higher rates of clinical remission and endoscopic response vs placebo during induction (U-EXCEL [NCT03345849], U-EXCEED [NCT03345836]) and maintenance (U-ENDURE...